Clinical Trial ResultsApellis reported better-than-expected, positive results for subq pegcetacoplan in two rare, serious kidney diseases (C3G/IC-MPGN).
Market PositionSyfovre maintained 50% of new patient starts despite being Izervay’s first quarter with a permanent J-code, and Syfovre still maintained 75% share of the total GA market based on number of patients treated.
Regulatory ApprovalProcedural changes have been made regarding the European Medicines Agency's review process, renewing optimism for a positive opinion on approval for pegcetacoplan in Europe.